{"id":142671,"title":"Fusion Antibodies wins new contract with returning pharmaceutical client","publisher":"Share Talk","author":"sharetalk","published":"2026-11-06T08:11:41+00:00","modified":"2026-11-06T08:11:41+00:00","canonical_url":"https://www.share-talk.com/fusion-antibodies-wins-new-contract-with-returning-pharmaceutical-client/","markdown_url":"https://www.share-talk.com/fusion-antibodies-wins-new-contract-with-returning-pharmaceutical-client.md","json_url":"https://www.share-talk.com/fusion-antibodies-wins-new-contract-with-returning-pharmaceutical-client.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Antibody","Belfast","FAB","Fusion Antibodies","National Cancer Institute","OptiMAL","Queen's University Belfast","Richard Buick","US federal government"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/11/378502e3-c767-4378-b4b7-73d385117de0.png?fit=1705%2C923&quality=80&ssl=1","format":"news","language":"en-GB","content":"[Fusion Antibodies plc (AIM: FAB)](https://www.investegate.co.uk/announcement/rns/fusion-antibodies--fab/further-contract-with-returning-client-/9861444) has secured a new antibody engineering contract worth more than £45,000 with an established European-listed global pharmaceutical customer, marking a further commercial win for its proprietary Rational Affinity Maturation Programme (RAMP) technology.\n\nThe Belfast-based specialist in pre-clinical antibody discovery, engineering and supply confirmed that the project will focus on **improving the binding affinity of the pharmaceutical company’s lead antibody**, using Fusion’s proprietary RAMP platform.\n\nThe contract is under an existing master services agreement, and Fusion has previously undertaken similar work for the same customer.\n\n**The project is expected to generate revenue exceeding £45,000 during Fusion’s current financial year**, with the associated work scheduled for completion within that period.\n\nAlthough relatively modest in financial terms, the award represents repeat business from an established pharmaceutical partner and supports Fusion’s strategy of developing longer-term commercial relationships with major drug developers.\n\n**RAMP is designed to improve the binding characteristics of antibodies**, an important consideration in therapeutic development where stronger or more precisely targeted interactions can contribute to the optimisation of potential drug candidates.\n\nThe programme involves technically complex engineering work, highlighting the specialist capabilities Fusion offers to pharmaceutical and biotechnology customers.\n\nThe new engagement also demonstrates the company’s ability to secure additional projects from existing clients without having to establish an entirely new commercial relationship.\n\n**Fusion is seeking to expand the commercial application of its technology portfolio**, which includes RAMP, its OptiMAL® antibody discovery platform and microfluidic cell line development capabilities.\n\nManagement believes that strengthening relationships with established pharmaceutical companies could create further opportunities for repeat contracts and support a more resilient revenue base.\n\n**Chief Executive Adrian Kinkaid** welcomed the award, describing the return of an existing global pharmaceutical customer as an encouraging endorsement of Fusion’s antibody engineering expertise.\n\nHe highlighted the opportunity to apply RAMP technology to the client’s lead antibody while continuing to build deeper relationships with pharmaceutical partners.\n\nThe company remains focused on delivering specialist antibody discovery and engineering services while increasing the commercial contribution from its proprietary platforms.\n\n**The latest contract provides additional revenue visibility for the current financial year**, although Fusion has not disclosed the exact contract value beyond confirming that it exceeds £45,000.\n\nThe identity of the pharmaceutical customer and the antibody’s intended therapeutic application have also not been disclosed.\n\n**For Fusion Antibodies, the significance of the award extends beyond its immediate financial contribution**, demonstrating continued customer engagement and further commercial use of its RAMP technology.\n\nThe announcement does not establish that further contracts will follow, but successful delivery could strengthen the existing relationship and provide opportunities for additional collaboration.\n\n**The company expects to complete the project within its current financial year**, adding to its contracted service revenues as it continues to develop commercial partnerships across the pharmaceutical sector."}